Vaxcyte/$PCVX
1D1W1MYTD1Y5YMAX
Capital at risk
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
- Ticker
- $PCVX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 507
- Headquarters
- San Carlos, United States
- Website
- vaxcyte.com
Vaxcyte Metrics
BasicAdvanced
$8.8B
-
-$7.65
1.21
-
Price and volume
Market cap
$8.8B
Beta
1.21
52-week high
$65.00
52-week low
$30.81
Average daily volume
1.1M
Financial strength
Current ratio
5.724
Quick ratio
5.481
Long term debt to equity
0.039
Total debt to equity
0.042
Profitability
EBITDA (TTM)
-1,148.78
Management effectiveness
Return on assets (TTM)
-22.61%
Return on equity (TTM)
-36.51%
Valuation
Price to book
3.11
Price to tangible book (TTM)
3.11
Price to free cash flow (TTM)
-8.946
Free cash flow yield (TTM)
-11.18%
Free cash flow per share (TTM)
-6.619
Growth
Earnings per share change (TTM)
85.35%
3-year earnings per share growth (CAGR)
32.95%
What the Analysts think about Vaxcyte
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Analyst projections of the future price of Vaxcyte stock.
Bulls say / Bears say
Approximately $2.5 billion in cash, cash equivalents and investments as of June 30, 2026 provides ample runway to advance VAX-31 and other pipeline programs through key clinical and commercial readiness milestones (GlobeNewswire).
Enrollment has completed for all three VAX-31 adult Phase 3 OPUS trials (OPUS-1, OPUS-2 and OPUS-3), with topline safety and immunogenicity data expected in Q4 2026, de-risking later-stage development and potential BLA submission (GlobeNewswire).
In June 2026 the company dosed the first participant in the Phase 1 adult study of VAX-A1, a novel Group A Streptococcus vaccine candidate, broadening Vaxcyte’s pipeline beyond pneumococcal conjugates and adding high-value early-stage diversification (GlobeNewswire).
Net loss widened to $284.3 million in Q2 2026, with R&D expenses climbing to $267.9 million driven by advanced clinical and manufacturing activities, underscoring a high cash burn rate before any product revenue (Bitget).
The pneumococcal conjugate vaccine market is dominated by established players like Pfizer’s Prevnar 20 and GSK’s emerging PCV25 program, raising the risk that Vaxcyte may struggle to differentiate VAX-31 and capture meaningful market share (SEC.gov).
Vaxcyte’s entry into an at-the-market sales agreement to sell up to $500 million of common stock signals ongoing reliance on equity financing and potential dilution for existing shareholders (MarketScreener).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
Vaxcyte Financial Performance
Revenues and expenses
Vaxcyte Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Vaxcyte
AllUSDGBPEUR
Fund name | Fund size | $PCVX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.57% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.57% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.25% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.15% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.